Table 1.

Characteristics of patients undergoing ASCT

Patients’ characteristicsOverall (n = 136)LEVO-group (n = 38)NO-LEVO-group (n = 98)P value
Baseline     
Age at ASCT, y, median (IQR) 59 (52-66) 63 (50-66) 58 (52-65) .86 
Male sex 87 (64%) 24 (63.2%) 63 (64.3%) .90 
Total number of ASCT for patient    .66 
First ASCT 104 (76.5%) 30 (78.9%) 74 (75.5%)  
Second ASCT 30 (22%) 8 (21.1%) 22 (22.5%)  
Third ASCT 2 (1.5%) 0 (0%) 2 (2%)  
Diagnosis    .82 
Myeloid disorders 4 (2.9%) 1 (2.6%) 3 (3.1%)  
Lymphoid disorders 127 (93.4%) 35 (92.1%) 92 (93.8%)  
Other disorders 5 (3.7%) 2 (5.3%) 3 (3.1%)  
Disease status at ASCT    .46 
Complete response 86 (63.2%) 21 (55.2%) 65 (66.3%)  
Active disease 45 (33.1%) 15 (39.5%) 30 (30.6%)  
Other 5 (3.7%) 2 (5.3%) 3 (3.1%)  
Ongoing line of therapy    .75 
First line 104 (76.5%) 29 (76.3%) 75 (76.5%)  
Second line 21 (15.4%) 5 (13.2%) 16 (16.3%)  
Third line 11 (8.1%) 4 (10.5%) 7 (7.2%)  
Conditioning chemotherapy    .75 
Myeloablative 120 (88.2%) 33 (86.8%) 87 (88.8%)  
Reduced intensity 16 (11.8%) 5 (13.2%) 11 (11.2%)  
ANC <500 cells/mm3 ≥ 7 d 0 (0%) 0 (0%) 0 (0%) 
MDR-GNB rectal carrier ≤30 d before ASCT 1 (0.7%) 0 (0%) 1 (1%) .53 
Antibiotics ≤90 d before ASCT 12 (8.8%) 0 (0%) 12 (12.2%) .02 
Follow-up     
Follow-up, d, median (IQR) 318 (153-596) 758 (188-964) 256 (149-523) .0001 
ANC engraftment 136 (100%) 38 (100%) 98 (100%) 
Time to engraftment, d, median (IQR) 11 (10-11.5) 11 (10-11) 11 (10-12) .82 
Relapse 22 (16.2%) 10 (26.3%) 12 (12.2%) .05 
Overall death 13 (9.6%) 7 (18.4%) 6 (6.1%) .03 
Causes of death    .13 
Disease 8 (5.9%) 5 (13.2%) 3 (3.1%)  
IRM 3 (2.2%) 1 (2.6%) 2 (2%)  
Others 2 (1.5%) 1 (2.6%) 1 (1%)  
Patients’ characteristicsOverall (n = 136)LEVO-group (n = 38)NO-LEVO-group (n = 98)P value
Baseline     
Age at ASCT, y, median (IQR) 59 (52-66) 63 (50-66) 58 (52-65) .86 
Male sex 87 (64%) 24 (63.2%) 63 (64.3%) .90 
Total number of ASCT for patient    .66 
First ASCT 104 (76.5%) 30 (78.9%) 74 (75.5%)  
Second ASCT 30 (22%) 8 (21.1%) 22 (22.5%)  
Third ASCT 2 (1.5%) 0 (0%) 2 (2%)  
Diagnosis    .82 
Myeloid disorders 4 (2.9%) 1 (2.6%) 3 (3.1%)  
Lymphoid disorders 127 (93.4%) 35 (92.1%) 92 (93.8%)  
Other disorders 5 (3.7%) 2 (5.3%) 3 (3.1%)  
Disease status at ASCT    .46 
Complete response 86 (63.2%) 21 (55.2%) 65 (66.3%)  
Active disease 45 (33.1%) 15 (39.5%) 30 (30.6%)  
Other 5 (3.7%) 2 (5.3%) 3 (3.1%)  
Ongoing line of therapy    .75 
First line 104 (76.5%) 29 (76.3%) 75 (76.5%)  
Second line 21 (15.4%) 5 (13.2%) 16 (16.3%)  
Third line 11 (8.1%) 4 (10.5%) 7 (7.2%)  
Conditioning chemotherapy    .75 
Myeloablative 120 (88.2%) 33 (86.8%) 87 (88.8%)  
Reduced intensity 16 (11.8%) 5 (13.2%) 11 (11.2%)  
ANC <500 cells/mm3 ≥ 7 d 0 (0%) 0 (0%) 0 (0%) 
MDR-GNB rectal carrier ≤30 d before ASCT 1 (0.7%) 0 (0%) 1 (1%) .53 
Antibiotics ≤90 d before ASCT 12 (8.8%) 0 (0%) 12 (12.2%) .02 
Follow-up     
Follow-up, d, median (IQR) 318 (153-596) 758 (188-964) 256 (149-523) .0001 
ANC engraftment 136 (100%) 38 (100%) 98 (100%) 
Time to engraftment, d, median (IQR) 11 (10-11.5) 11 (10-11) 11 (10-12) .82 
Relapse 22 (16.2%) 10 (26.3%) 12 (12.2%) .05 
Overall death 13 (9.6%) 7 (18.4%) 6 (6.1%) .03 
Causes of death    .13 
Disease 8 (5.9%) 5 (13.2%) 3 (3.1%)  
IRM 3 (2.2%) 1 (2.6%) 2 (2%)  
Others 2 (1.5%) 1 (2.6%) 1 (1%)  

or Create an Account

Close Modal
Close Modal